Issue: July 2013
July 01, 2013
1 min read
Save

VIVIDD

Issue: July 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers investigated the effects of vildagliptin in patients with type 2 diabetes and HF with reduced ejection fraction.

VIVIDD